Chronic Lymphocytic Leukemia | Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences
Research To Practice | Oncology Videos · Dr. Neil Love
April 12, 20241h 34m
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring perspectives from Dr Bita Fakhri, including the following topics:
- Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00)
- 6-year follow-up from the Phase III CLL14 trial of first-line venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for chronic lymphocytic leukemia (CLL) (7:36)
- Updates from ASH 2023 from the Phase III FLAIR study of minimal residual disease (MRD)-guided ibrutinib in combination with venetoclax for previously untreated CLL (13:28)
- 57-month follow-up from the Phase III GLOW trial of fixed-duration ibrutinib/venetoclax for previously untreated CLL (22:28)
- Current clinical role of MRD testing for CLL (28:11)
- Key findings from 5-year follow-up of the Phase II CAPTIVATE study for patents with CLL/small lymphocytic leukemia (SLL) with relapse after first-line fixed-duration ibrutinib/venetoclax (36:43)
- 6-year update from the Phase III ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for treatment-naïve CLL (41:57)
- Updates from ASH 2023 for the management of relapsed/refractory CLL (54:30)
- Recent updates for the management of double-refractory CLL (58:05)
- Novel therapies under investigation for patients with CLL/SLL (1:10:57)
- Key findings guiding the clinical management of Richter's transformation (1:13:44)
- Case: A man in his early 80s with IGHV-unmutated del(17p) CLL experiences disease progression 3 years after completing second-line venetoclax-based therapy (1:22:17)